Shots:
- Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and commercial milestones along with royalties & gets the option to take part in product development in exchange for higher royalty rates
- Post pre-clinical research and development activities, AbbVie has an option to license the program and proceed with IND-enabling studies, clinical development, and commercialization
- The collaboration leverages Caraway’s drug discovery platform, expertise in lysosomal biology & cellular clearance mechanisms combine with AbbVie’s expertise in disease biology, clinical development, and global commercialization
Click here to read full press release/ article | Ref: Business Wire | Image: Business Wire
The post AbbVie Collaborates with Caraway to Develop TMEM175 for Parkinson’s Disease and Other Related Disorders first appeared on PharmaShots.
